<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219908">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00221104</url>
  </required_header>
  <id_info>
    <org_study_id>J-STARS</org_study_id>
    <secondary_id>C000000207</secondary_id>
    <nct_id>NCT00221104</nct_id>
  </id_info>
  <brief_title>Japan Statin Treatment Against Recurrent Stroke (J-STARS)</brief_title>
  <official_title>Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Informatics Center, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hiroshima University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Informatics Center, Kobe, Hyogo, Japan</source>
  <brief_summary>
    <textblock>
      Although hyperlipidemia is not always the risk factor of stroke, inhibition of
      3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can decrease the incidence of
      stroke in the patient with ischemic heart disease. The neuroprotective mechanism beyond
      cholesterol lowering should be expected to attenuate inflammation and atherosclerosis. The
      present study hypothesizes if pravastatin prevents recurrent stroke in the ischemic stroke
      patients with safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cerebrovascular events</measure>
    <time_frame>until the last day of the next February after 5-year follow-up survey</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>subtype of ischemic stroke according to the TOAST classification or hemorrhagic stroke, cardiovascular events including myocardial infarction, all the cerebrovascular and cardiovascular events, death of stroke, death of cerebrovascular and cardiovascular</measure>
    <time_frame>until the last day of the next February after 5-year follow-up survey</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1578</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient has no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <arm_group_label>Pravastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic stroke except for cardiogenic embolism, from 1 month to 3 years after onset

          -  Hyperlipidemia and total cholesterol level of 180-240mg/dl without the prescription
             of statin within previous 30 days

          -  Able to visit outpatient department

          -  Informed consent on the form.

        Exclusion Criteria:

          -  Ischemic stroke of other determined cause according to the TOAST classification

          -  Ischemic heart disease and necessary to use statin

          -  Hemorrhagic disorders

          -  Platelet count &lt;=100,000/ul within 3 months prior to study start

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&gt;= 100IU/L within 3
             months prior to study start

          -  Serum creatinine &gt;=2.0mg/dl within 3 months prior to study start

          -  A scheduled operation

          -  The presence of malignant disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masayasu Matsumoto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hiroshima University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://jstars.umin.ne.jp</url>
    <description>Japan Statin Treatment Against Recurrent Stroke (J-STARS) only in Japanese</description>
  </link>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>April 22, 2016</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>brain ischemia</keyword>
  <keyword>cerebrovascular accident</keyword>
  <keyword>statin</keyword>
  <keyword>hydroxymethylglutaryl-CoA reductase inhibitors</keyword>
  <keyword>cholesterol</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>hyperlipidemia</keyword>
  <keyword>multicenter studies</keyword>
  <keyword>prospective studies</keyword>
  <keyword>endpoint determination</keyword>
  <keyword>randomized controlled trials</keyword>
  <keyword>recurrence</keyword>
  <keyword>pravastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
